News Articles

Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million... OSAKA, Japan -Monday 21 December 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a...

Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade -Friday 11 December 2020

Company Aiming for Mid-Single-Digit Revenue CAGR Over Next Decade Amounting to JPY5 Trillion ($47 Billion) by FY20301 Wave 1 Pipeline Portfolio Includes 12 New Molecular Entities Targeted for Launch by FY2024 Representing Best-in-Class/First-in-Class Therapies Near-Term Late-Development...

Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments... -Thursday 10 December 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition that underscore its commitment to advancing...

Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the... -Tuesday 8 December 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that China’s National Medical Products Administration (NMPA) has approved TAKHZYRO® (lanadelumab) subcutaneous injection for prophylaxis to prevent attacks of hereditary angioedema...

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with... -Friday 4 December 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with...

Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific -Tuesday 1 December 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive of milestone payments....

Final Results from the Phase 3 HELP Study Open-Label Extension Support TAKHZYRO®... -Friday 13 November 2020

Study Results Showed Long-term Findings Consistent with the Known Safety Profile of TAKHZYRO with Reductions in the Rate of HAE Attacks and Attack-free Periods Data Presented at the 2020 American College of Allergy, Asthma and Immunology Virtual Annual Scientific Meeting (BUSINESS...

Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual... -Monday 9 November 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting, being held virtually December 5-8, 2020. The company’s scientific...

Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts... -Tuesday 3 November 2020

FY2020 H1 results driven by growth of global brands (e.g. Entyvio +25.8% YOY, TAKHZYRO +45.5% YOY, NINLARO + 19.2% YOY); generated strong margins and cash flow R&D engine continues to advance Wave 1 pipeline, with cell therapy capabilities expanded Confirming full-year management guidance...

Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan -Saturday 31 October 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a...

Takeda Accelerates Digital Transformation with Accenture and AWS -Tuesday 13 October 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”), Accenture (NYSE: ACN) and Amazon Web Services, Inc. (AWS) have entered into a five-year strategic agreement to accelerate Takeda’s digital transformation. Not only will patients benefit from...

Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults... -Monday 12 October 2020

Interim analysis from VISIBLE OLE study showed long-term findings consistent with the known safety profile of vedolizumab with maintained rates of clinical remission and corticosteroid-free clinical remission Entyvio® was the first maintenance biological therapy approved across Europe in...

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver... -Friday 9 October 2020  

Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M Investigational...

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress -Sunday 20 September 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase...

Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs -Thursday 17 September 2020    

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston,...

Takeda to Divest TachoSil® to Corza Health for €350 Million -Wednesday 16 September 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest its TachoSil® Fibrin Sealant Patch (“TachoSil®”) to Corza Health, Inc. (“Corza Health”). Corza Health was formed in 2019 as a...

Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple... -Monday 14 September 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3 TOURMALINE-MM2 trial evaluating the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo in newly...

Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD -Tuesday 8 September 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm. Cheplapharm is a...

Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with... -Thursday 27 August 2020  

− Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo (p=0.0007) in the combined Dravet syndrome and Lennox-Gastaut syndrome study population − Statistically significant reduction in seizure frequency from baseline...

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan -Saturday 8 August 2020  

(BUSINESS WIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and...